You are here

Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-18-P-0318
Agency Tracking Number: C18A-001-0009
Amount: $149,947.05
Phase: Phase I
Program: STTR
Solicitation Topic Code: CBD18A-001
Solicitation Number: 2018.0
Solicitation Year: 2018
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-19
Award End Date (Contract End Date): 2019-03-28
Small Business Information
701 McMillian Way NW Suite D
Huntsville, AL 35806
United States
DUNS: 185169620
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Narender Singh
 (256) 726-4800
Business Contact
 Tanu Singhal
Phone: (256) 726-4924
Research Institution
 George Mason University
 Michael Laskofski
Biomedical Research Laboratory 10650 Pyramid Place
Manassas, VA 20110
United States

 (703) 993-5409
 Nonprofit College or University

In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and rapid diagnostics.We propose to undertake a systematic study to identify and validate the circulatory RNAs and the potential exosomal-based biomarkers ofVEEV infection using mouse models. Multiple clinical matrices (urine, blood, CSF, lymph) and infection routes (intranasal, subcutaneous) will bestudied to analyze the RNA biomarker dynamics in a specified diagnostic window (0-14 days, post infection). Exosome contents (e.g., miRNA)and other host-based biomarkers will also be analyzed and compared for specificity and sensitivity. Finally, we will integrate the animaloutcome in computational models to predict viral kinetics, translation of findings from animals to humans, and to make predictions ofprognostic factors for treatment efficacy and the risk of relapse and progression. Ultimately, we envision to develop a low cost, in vitrodiagnostic device for rapid and sensitive detection of pre-symptomatic, symptomatic or convalescent biomarkers of these infectious diseases.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government